Welcome to LookChem.com Sign In|Join Free

CAS

  • or

845614-12-2

RO4917838 (R enantiomer) is a selective and potent inhibitor of the histone lysine methyltransferase G9a, a critical regulator of gene expression. It effectively reduces G9a-dependent H3K9me2 levels in cells, leading to the suppression of cancer cell growth and proliferation. RO4917838 (R enantioMer) exhibits high selectivity for G9a, with minimal off-target effects, and has potential as a promising therapeutic agent in cancer treatment.
Used in Pharmaceutical Industry:
RO4917838 (R enantiomer) is used as an anticancer agent for its ability to effectively inhibit the growth of various cancer cell lines in vitro. Its high selectivity for G9a and minimal off-target effects make it a promising candidate for cancer treatment.
Used in Neurodegenerative Disease Research:
RO4917838 (R enantiomer) is being investigated for its role in modulating immune response and as a potential treatment for neurodegenerative diseases, due to its ability to target the G9a enzyme, which may play a role in the progression of these conditions.

845614-12-2

Post Buying Request

845614-12-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

  • Methanone, [4-[3-fluoro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl][5-(methylsulfonyl)-2-[(1R)-2,2,2-trifluoro-1-methylethoxy]phenyl]-

    Cas No: 845614-12-2

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier

845614-12-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 845614-12-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,6,1 and 4 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 845614-12:
(8*8)+(7*4)+(6*5)+(5*6)+(4*1)+(3*4)+(2*1)+(1*2)=172
172 % 10 = 2
So 845614-12-2 is a valid CAS Registry Number.

845614-12-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name Methanone, [4-[3-fluoro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl][5-(methylsulfonyl)-2-[(1R)-2,2,2-trifluoro-1-methylethoxy]phenyl]-

1.2 Other means of identification

Product number -
Other names Piperazine, 1-[3-fluoro-5-(trifluoromethyl)-2-pyridinyl]-4-[5-(methylsulfonyl)-2-[(1R)-2,2,2-trifluoro-1-methylethoxy]benzoyl]-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:845614-12-2 SDS

845614-12-2Upstream product

845614-12-2Downstream Products

845614-12-2Relevant articles and documents

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

Pinard, Emmanuel,Alanine, Alexander,Alberati, Daniela,Bender, Markus,Borroni, Edilio,Bourdeaux, Patrick,Brom, Virginie,Burner, Serge,Fischer, Holger,Hainzl, Dominik,Halm, Remy,Hauser, Nicole,Jolidon, Synese,Lengyel, Judith,Marty, Hans-Peter,Meyer, Thierry,Moreau, Jean-Luc,Mory, Roland,Narquizian, Robert,Nettekoven, Mathias,Norcross, Roger D.,Puellmann, Bernd,Schmid, Philipp,Schmitt, Sebastien,Stalder, Henri,Wermuth, Roger,Wettstein, Joseph G.,Zimmerli, Daniel

experimental part, p. 4603 - 4614 (2010/09/17)

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 845614-12-2